XBiotech (STU:4XB) Total Receivables: €0.26 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4XB XBiotech Inc STU:4XB
39 GF Score
Price €2.00
! 2 Warning Signs
View Full Analysis

What is XBiotech Total Receivables?

XBiotech STU:4XB -1.72% 39 Total Receivables is €0.26 Mil as of Mar. 2026. GuruFocus rates STU:4XB with a GF Score™ of 39/100. The stock has 2 warning signs investors should review.

XBiotech's Total Receivables for the quarter that ended in Mar. 2026 was €0.26 Mil.

XBiotech Total Receivables Historical Data

* Premium members only.

The historical data trend for XBiotech's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XBiotech Total Receivables Chart

XBiotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.92 1.67 0.86 0.82 0.31

XBiotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.55 0.45 0.31 0.26
STU:4XB
39GF Score
XBiotech Inc STU:4XB
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

XBiotech Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.26 Mil mean?
XBiotech (STU:4XB) has a Total Receivables of €0.26 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on XBiotech and its competitors.
Is XBiotech's Total Receivables too high?
XBiotech's current Total Receivables is €0.26 Mil. Overall, XBiotech has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does XBiotech's Total Receivables compare to ACRV and EXOZ?
XBiotech's Total Receivables of €0.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on XBiotech and its competitors. XBiotech's current Total Receivables is €0.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is XBiotech stock overvalued right now?
XBiotech (STU:4XB) has a current Total Receivables of €0.26 Mil. The current Total Receivables is €0.26 Mil. XBiotech's overall GF Score™ is 39/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For XBiotech (STU:4XB), the current Total Receivables is €0.26 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

XBiotech Business Description

Other Exchanges XBIT:USA
Address 5217 Winnebago Lane, Austin, TX, USA, 78744
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
39GF Score

Get the complete analysis for STU:4XB

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.00
Price